Novocure (NVCR) Stock Forecast & Price Target

NovoCure Ltd has demonstrated a positive revenue trend with a 4% increase in 4Q25 revenue to $174.4 million, surpassing estimates due to stronger domestic sales of Optune Gio, and achieving full-year revenue of $655.4 million, reflecting an 8% growth from the previous year. The company’s expansion into the international market has been bolstered by national reimbursement in Spain, which is expected to significantly enhance revenue streams in 2026. Additionally, with promising clinical trial results and expectations of continued growth in the U.S. market, NovoCure is well-positioned for potential increases in market penetration and revenue generation moving forward.

NovoCure Ltd has reported a slight increase in revenue for its NSCLC segment, rising to $1.6 million in 3Q25, but overall revenues from Optune Lua are described as flat, indicating stagnant growth. The company has decreased its 2026 revenue estimates for Glioblastoma (GBM) to $690 million, alongside a reduction in total revenue estimates to $711.3 million, down from $738.9 million previously forecasted, reflecting concerns over sales performance and adoption rates for its products. Additional risks impacting NovoCure's outlook include potential safety and efficacy issues with ongoing clinical trials, increased competition from alternative treatments, and regulatory challenges, all of which could hinder financial performance and market position.